ARRY-382

• Description :

  ARRY-382 is a potent, oral and highly selective inhibitor of CSF1R/c-Fms with an IC50 of 9 nM. ARRY-382 can be used for the research of advanced or metastatic cancers[1].

• CAS Number :

  [1313407-95-2]

• UNSPSC :

  12352005

• Target :

  C-Fms

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/c-fms-in-12.html

• Purity :

  99.95

• Solubility :

  DMSO : 8.33 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=CN=C2C=C(OCCN3CCN(C)CC3)C=CN21)NC4=CC=CC5=C4C(C6CC6)=NN5CC7=NC(C)=CC=C7

• Molecular Formula :

  C32H36N8O2

• Molecular Weight :

  564.68

• References & Citations :

  [1]David K Edwards V, et al. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 2018 May 15;9 (37) :24576-24589.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2